AstraZeneca: Fasenra Trial In EoE Did Not Meet One Of Two Dual-primary Endpoints

LONDON (dpa-AFX) - British drug major AstraZeneca PLC (AZN.L) Tuesday announced that MESSINA Phase III trial for Fasenra (benralizumab) failed to meet one of the two dual-primary endpoints in eosinophilic

Related Keywords

Japan ,United Kingdom ,London ,City Of ,British , ,Astrazeneca ,Biowa Inc ,Kyowa Kirin Co Ltd ,More Such Health News ,Executive Vice President ,Fasenra ,Trial ,Feet ,Ual ,Primary ,Endpoints ,